Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

Articles

Sort by
Previous Page Page 1 of 60 Next Page
  1. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase ...

    Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:7

    Published on:

  2. Content type: Case report

    The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first tim...

    Authors: Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler and Lucie Heinzerling

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:2

    Published on:

  3. Content type: Case report

    Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not be...

    Authors: Christopher A. Barker, Samuel K. Kim, Sadna Budhu, Konstantina Matsoukas, Anthony F. Daniyan and Sandra P. D’Angelo

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:1

    Published on:

  4. Content type: Research article

    Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors.

    Authors: Rachel E. Sanborn, Helen J. Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:103

    Published on:

  5. Content type: Research article

    Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads t...

    Authors: Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan Emberley, Tony Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele Marguier, Peter J. Murray, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L. M. Rodriguez, Lee-Ann Van de Velde…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:101

    Published on:

  6. Content type: Research article

    We have previously shown that radiotherapy (RT) augments natural killer (NK) functions in pre-clinical models of human and mouse cancers, including sarcomas. Since dogs are an excellent outbred model for immun...

    Authors: Robert J. Canter, Steven K. Grossenbacher, Jennifer A. Foltz, Ian R. Sturgill, Jiwon S. Park, Jesus I. Luna, Michael S. Kent, William T. N. Culp, Mingyi Chen, Jaime F. Modiano, Arta M. Monjazeb, Dean A. Lee and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:98

    Published on:

  7. Content type: Research article

    Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact ...

    Authors: Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong and Janice P. Dutcher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:102

    Published on:

  8. Content type: Research article

    Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with r...

    Authors: Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky and Christian Grommes

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:99

    Published on:

  9. Content type: Case report

    There has been a significant improvement in survival of advanced malignancies with the advent of checkpoint inhibitors. These newer treatment modalities come with a wide spectrum of unique side effects, termed...

    Authors: Pouyan N. Changizzadeh, Shiva Kumar R. Mukkamalla and Vincent A. Armenio

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:97

    Published on:

  10. Content type: Research article

    Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicine...

    Authors: Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam and Vivek Subbiah

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:100

    Published on:

  11. Content type: Commentary

    Commentary on « Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade » by Läubli H et al., J Immunother Cancer. 2017;5:46.

    Authors: Roger Sun, Francois-Xavier Danlos, Samy Ammari, Guillaume Louvel, Frédéric Dhermain, Stéphane Champiat, Olivier Lambotte and Eric Deutsch

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:96

    Published on:

  12. Content type: Research article

    Hepatocellular carcinoma (HCC) is a major health problem worldwide with increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this inflammation aids to drive oncogenesis and o...

    Authors: Zachary J. Brown, Bernd Heinrich, Seth M. Steinberg, Su Jong Yu and Tim F. Greten

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:93

    Published on:

  13. Content type: Research article

    Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of d...

    Authors: Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:92

    Published on:

  14. Content type: Review

    With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Authors: Adam Ajina and John Maher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:90

    Published on:

  15. Content type: Research article

    Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit ...

    Authors: Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz and Wilson H. Miller Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:83

    Published on:

  16. Content type: Review

    Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    Authors: David H. Aggen and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:94

    Published on:

  17. Content type: Position article and guidelines

    Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a d...

    Authors: I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham III, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:95

    Published on:

  18. Content type: Research article

    It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in ...

    Authors: Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim and Jing Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:85

    Published on:

  19. Content type: Case report

    Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have show...

    Authors: Gustavo dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes and Renata de Almeida Coudry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:84

    Published on:

  20. Content type: Case report

    Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of...

    Authors: Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi and Robert M. Conry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:91

    Published on:

  21. Content type: Correction

    Authors: Veronika Kremer, Maarten A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:88

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:73

Previous Page Page 1 of 60 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement